Intravenous Iron Supplementation Practices and Short-Term Risk of Cardiovascular Events in Hemodialysis Patients
Open Access
- 1 November 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11), e78930
- https://doi.org/10.1371/journal.pone.0078930
Abstract
Intravenous iron supplementation is widespread in the hemodialysis population, but there is uncertainty about the safest dosing strategy. We compared the safety of different intravenous iron dosing practices on the risk of adverse cardiovascular outcomes in a large population of hemodialysis patients. A retrospective cohort was created from the clinical database of a large dialysis provider (years 2004-2008) merged with administrative data from the United States Renal Data System. Dosing comparisons were (1) bolus (consecutive doses ≥ 100 mg exceeding 600 mg during one month) versus maintenance (all other iron doses during the month); and (2) high (> 200 mg over 1 month) versus low dose (≤ 200 mg over 1 month). We established a 6-month baseline period (to identify potential confounders and effect modifiers), a one-month iron exposure period, and a three-month follow-up period. Outcomes were myocardial infarction, stroke, and death from cardiovascular disease. 117,050 patients contributed 776,203 unique iron exposure/follow-up periods. After adjustment, we found no significant associations of bolus dose versus maintenance, hazards ratio for composite outcome, 1.03 (95% C.I. 0.99, 1.07), or high dose versus low dose intravenous iron, hazards ratio for composite outcome, 0.99 (95% C.I. 0.96, 1.03). There were no consistent associations of either high or bolus dose versus low or maintenance respectively among pre-specified subgroups. Strategies favoring large doses of intravenous iron were not associated with increased short-term cardiovascular morbidity and mortality. Investigation of the long-term safety of the various intravenous iron supplementation strategies may still be warranted.This publication has 35 references indexed in Scilit:
- Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohortNephrology, 2010
- Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPSNephrology Dialysis Transplantation, 2008
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseThe New England Journal of Medicine, 2006
- HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Intravenous Iron Therapy in End-Stage Renal DiseaseSeminars in Dialysis, 2006
- The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremiaKidney International, 2002
- Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery Intima-Media Thickness in End-Stage Renal DiseaseCirculation, 2002
- Review of issues relating to iron and infectionAmerican Journal of Kidney Diseases, 1999
- The role of oxidized lipoproteins in atherogenesisFree Radical Biology & Medicine, 1996
- Semiparametric analysis of the additive risk modelBiometrika, 1994
- Superoxide dependent iron release from ferritin in inflammatory diseasesFree Radical Biology & Medicine, 1988